eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

3/2020
vol. 12
 
Share:
Share:
more
 
 
abstract:
Original paper

Iodine-125 seed implantation for residual hepatocellular carcinoma or cholangiocellular carcinoma in challenging locations after transcatheter arterial chemoembolization. Initial experience and findings

Jie Li
1
,
Lijuan Zhang
2
,
Zongqiong Sun
3
,
Yuxi Ge
3
,
Han Xiao
4
,
Qigen Xie
1
,
Shudong Hu
3

1.
Department of Interventional Radiology, the Affiliated Hospital of Jiangnan University (Wuxi 4th People’s Hospital), Wuxi, Jiangsu Province, China
2.
Department of Radiology, Wuxi People’s Hospital of Nanjing Medical University, Wuxi, Jiangsu, China
3.
Department of Radiology, the Affiliated Hospital of Jiangnan University (Wuxi 4th People’s Hospital), Wuxi, Jiangsu Province, China
4.
Department of Traditional Chinese Medicine, the Affiliated Hospital of Jiangnan University (Wuxi 4th People’s Hospital), Wuxi, Jiangsu Province, China
J Contemp Brachytherapy 2020; 12, 3: 233–240
Online publish date: 2020/06/30
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
To evaluate the clinical efficacy and safety of computed tomography (CT)-guided iodine-125 (125I) seed implantation (ISI) for hepatocellular carcinoma (HCC) or cholangiocellular carcinoma (CCC) lesions in challenging locations after transcatheter arterial chemoembolization (TACE).

Material and methods
A retrospective single-center review of 24 patients with HCC or CCC tumors in challenging locations (hepatic dome or close to the heart/diaphragm/hepatic hilum) was conducted. Patients who underwent CT-guided 125I implantation from May 2014 to January 2019 were recruited. Patients’ demographics and details including technical success, treatment response, patient survival, and complication rate were also evaluated.

Results
Treated tumors were located in the hepatic dome (n = 10; 41.7%), subcapsularly (n = 6; 25%), close to the heart (n = 3; 12.5%), and in the liver hilum (n = 5; 20.8%). The mean maximum diameter of tumors in challenging locations was 40.08 ±11.34 mm (range, 25-68 mm). TACE (2 ±1, 1-4 times) was applied before ISI. There were 27 ISI treatments administered (3 patients also received supplemental ISI). The total number of implanted seeds was 1,160, with mean 48 ±16 seed per patient (range, 30-90 seeds). The mean D90 value for ISI was 125 Gy. Technical success rate was 100%, while a complete response + partial response (CR + PR) was documented in 70.83%, 79.17%, 83.33%, and 79.17% of patients at 3, 6, 12, and 24 months post-ISI, respectively. There were no major complications, although 2 cases experienced 125I seed transfer to the diaphragm, and 1 case experienced transfer to the heart cavity.

Conclusions
CT-guided ISI for HCC or CCC lesions in challenging locations after TACE is both highly effective and safe.

keywords:

liver neoplasms, iodine-125, computed tomography, neoplasm, residual, chemoembolization, therapeutic

 
Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe